A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib

The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administered at 10...

Descripción completa

Detalles Bibliográficos
Autores principales: Castillo, Jorge J., Sarosiek, Shayna, Flynn, Catherine A., Leventoff, Carly, Little, Megan, White, Timothy, Meid, Kirsten, Treon, Steven P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421949/
https://www.ncbi.nlm.nih.gov/pubmed/36051045
http://dx.doi.org/10.1002/jha2.493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421949/
https://www.ncbi.nlm.nih.gov/pubmed/36051045
http://dx.doi.org/10.1002/jha2.493

Ejemplares similares